Skip to main content

 

 

Back by $6.4 million in private funding, a new Neuroscape Psychedelics Division at the University of California, San Francisco will focus on the delivery of more personalized and precise psychedelic treatments.
Perspectives
Ketamine has been demonstrated to be effective in treating mental health disorders, chronic pain and addiction by causing several developments in key areas of the brain associated with these conditions.
Psychedelic Medicine Association president Lynn Marie Morski, MD, Esq., a Sana Symposium steering committee member, discusses the mission of the Psychedelic Medicine Association, bringing psychedelics education to front-line providers who are…
Findings in a recently published research review could help guide practitioners in future studies to identify patients who are more likely to have adverse reactions to psychedelics and adjust dosages accordingly.
The University of Wisconsin-Madison on Tuesday announced the launch of a master’s training program in psychedelic science. The program, which will be fully online, is the first of its kind in the U.S.
Back to Top